Domo signs strategic collaboration agreement with AWS for AI solutions
DA Davidson raised its price target on Paysign Inc. (NASDAQ:PAYS) to $8.00 from $7.00 on Friday, while maintaining a Buy rating on the payment solutions provider. Currently trading at $4.96, the stock has analyst targets ranging from $6.50 to $8.25, with a strong Buy consensus. The price target increase follows Paysign’s announcement last week about securing 132 established plasma donation centers. InvestingPro analysis reveals 12 additional key insights about PAYS’s potential.
The company won these centers through an expansion of its relationship with a major plasma collection company. This addition will increase Paysign’s total plasma locations to 613 centers, representing a 27% increase from the 484 locations it served at the end of the first quarter of 2025. The expansion comes as Paysign demonstrates strong financial performance, with revenue growing 26.77% and maintaining a healthy gross profit margin of 57.92%.
DA Davidson cited this significant expansion as the basis for raising its financial forecasts for 2025 and 2026. The firm also introduced new forecasts for 2027 in its research note.
The research firm’s analyst noted, "Last week, Paysign announced the company had been awarded 132 established plasma donation centers through an expansion of a relationship with a major plasma collection company."
Paysign specializes in prepaid card programs, digital banking services, and payment processing for corporate clients, with a significant presence in the plasma collection industry where its payment solutions are used for donor compensation. The company maintains a "GOOD" overall financial health score according to InvestingPro metrics, with detailed analysis available in the comprehensive Pro Research Report, part of the platform’s coverage of over 1,400 US stocks.
In other recent news, Paysign Inc. announced impressive first-quarter earnings results, significantly surpassing analyst expectations. The company reported an earnings per share (EPS) of $0.05, which was notably higher than the forecasted $0.01, and revenue of $18.6 million, exceeding the anticipated $15.11 million. This marks a 41% increase in revenue year-over-year and a dramatic 193% rise in adjusted EBITDA. Following these strong results, DA Davidson raised its price target for Paysign from $5.00 to $6.00, maintaining a Buy rating on the company’s shares.
Paysign also revealed plans to expand its plasma donation center network, adding 132 centers, which is expected to significantly increase its U.S. market share in plasma donor compensation programs. The expansion is projected to contribute fully to revenues by the end of the first quarter of 2026. Additionally, Paysign held its annual stockholders meeting, where all seven nominees for the Board of Directors were elected, and Moss Adams LLP was ratified as the independent auditor for the fiscal year.
The company has set a total revenue guidance of $72-74 million for 2025, anticipating a 25% growth, with pharma revenue expected to grow by 135%. Paysign remains debt-free with $6.9 million in unrestricted cash, reflecting its strong financial health. These developments highlight Paysign’s strategic growth initiatives and robust financial performance, drawing attention from investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.